Genetic immunization
The aim of this project is to design mRNA vectorization strategies for vaccine applications against infectious diseases. The antigen against which the immune response is sought is encoded in the in vitro transcribed mRNA molecule (IVT-mRNA).
Schematic representation of a synthetic mRNA encoding a multi-epitope antigen
Vectorization strategies are required to give mRNA access to the cellular machinery, enabling in situ production of the antigen and the onset of the immune response against it. Unlike plasmid DNA, mRNA does not need to be transported to the nucleus, as it is translated in the cytoplasm. We intend to formulate mRNA-IVT molecules in our self-assembling nanoparticle vectors and administer them via different routes to assess the humoral and cellular immune response induced by expression of the mRNA-IVT-encoded antigen. Two vaccine applications are envisaged: (i) Immunization against Chagas disease in collaboration with Dr Alonso-Padillala and Pr Gascón, University of Barcelona, (ii) Immunization against gestational malaria in collaboration with Dr Ndam, MERIT laboratory “Mère et enfant avec infections tropicales”, IRD University of Paris.
Thesis defense at UTCBS: Monica Swetha Bosco “Fingerprint Approach Using Macrocyclic Chemical Nose Sensors for Disease Diagnostics”
Thesis defense at UTCBS: Monica Swetha Bosco “Fingerprint Approach Using Macrocyclic Chemical Nose Sensors for Disease Diagnostics”
Thesis defense at UTCBS: Nasir Arafath “Functionalization and Evaluation of Antioxidant Cerium Oxide Nanoparticles for Stroke Treatment.
Thesis defense at UTCBS: Nasir Arafath
For the 2nd year running, UTCBS is hosting a delegation of South African researchers as part of a bilateral PHC
For the 2nd year running, UTCBS is hosting a delegation of South African researchers as part of a bilateral PHC
CNRS honors Néovacs and UTCBS, united for a therapeutic RNA vaccine against asthma
Suresnes, August 29, 2024 - 8am CET - Neovacs (Euronext Growth Paris : ALNEV), a preclinical-stage biopharmaceutical company developing novel therapies for inflammatory and autoimmune diseases, is honored to be listed among the latest CNRS publications following the...